LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 24 of 66
Next
>>
>
576 to 600 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Vorinostat	180615_MC_08	772	0.1347	67	46	12	16	Vorinostat	9.98	treatment	72	1	MCF10A-GM_9	113	0.1277	586.3	196.0	12428	298.5	0.0234	0.10429	0.0645
Alpelisib	180619_MC_10	15639	0.0226	71	284	7	14	Alpelisib	0.003326667	treatment	72	2	MCF10A-GM_1	355	0.0222	635.9	71.1	15071	356.7	0.0231	-0.00088	1.0163
Alpelisib	180619_MC_10	15238	0.0224	64	279	8	11	Alpelisib	0.003326667	treatment	72	2	MCF10A-GM_2	343	0.0220	635.9	71.1	15071	356.7	0.0231	-0.00106	1.0048
Alpelisib	180619_MC_10	14102	0.0172	44	199	12	14	Alpelisib	0.003326667	treatment	72	2	MCF10A-GM_3	243	0.0169	635.9	71.1	15071	356.7	0.0231	-0.00613	0.9711
Alpelisib	180619_MC_11	13705	0.0232	81	239	3	13	Alpelisib	0.003326667	treatment	72	2	MCF10A-GM_4	320	0.0228	635.9	71.1	15071	356.7	0.0231	-0.00026	0.9588
Alpelisib	180619_MC_11	15246	0.0234	65	294	8	17	Alpelisib	0.003326667	treatment	72	2	MCF10A-GM_5	359	0.0230	635.9	71.1	15071	356.7	0.0231	-0.00007	1.0051
Alpelisib	180619_MC_11	14336	0.0190	47	226	13	15	Alpelisib	0.003326667	treatment	72	2	MCF10A-GM_6	273	0.0187	635.9	71.1	15071	356.7	0.0231	-0.00439	0.9782
Alpelisib	180619_MC_12	14666	0.0245	128	234	9	21	Alpelisib	0.003326667	treatment	72	2	MCF10A-GM_7	362	0.0241	635.9	71.1	15071	356.7	0.0231	0.00101	0.9881
Alpelisib	180619_MC_12	15513	0.0292	157	301	11	6	Alpelisib	0.003326667	treatment	72	2	MCF10A-GM_8	458	0.0287	635.9	71.1	15071	356.7	0.0231	0.00560	1.0127
Alpelisib	180619_MC_12	14538	0.0216	59	257	13	22	Alpelisib	0.003326667	treatment	72	2	MCF10A-GM_9	316	0.0213	635.9	71.1	15071	356.7	0.0231	-0.00180	0.9843
Alpelisib	180619_MC_10	14504	0.0275	78	323	3	12	Alpelisib	0.00998	treatment	72	2	MCF10A-GM_1	401	0.0269	635.9	71.1	15071	356.7	0.0231	0.00383	0.9833
Alpelisib	180619_MC_10	14011	0.0189	34	231	13	15	Alpelisib	0.00998	treatment	72	2	MCF10A-GM_2	265	0.0186	635.9	71.1	15071	356.7	0.0231	-0.00451	0.9683
Alpelisib	180619_MC_10	14043	0.0184	51	208	13	21	Alpelisib	0.00998	treatment	72	2	MCF10A-GM_3	259	0.0181	635.9	71.1	15071	356.7	0.0231	-0.00496	0.9693
Alpelisib	180619_MC_11	14546	0.0216	55	260	5	4	Alpelisib	0.00998	treatment	72	2	MCF10A-GM_4	315	0.0212	635.9	71.1	15071	356.7	0.0231	-0.00188	0.9845
Alpelisib	180619_MC_11	14357	0.0197	87	198	10	21	Alpelisib	0.00998	treatment	72	2	MCF10A-GM_5	285	0.0195	635.9	71.1	15071	356.7	0.0231	-0.00361	0.9789
Alpelisib	180619_MC_11	15319	0.0202	57	253	12	5	Alpelisib	0.00998	treatment	72	2	MCF10A-GM_6	310	0.0198	635.9	71.1	15071	356.7	0.0231	-0.00324	1.0072
Alpelisib	180619_MC_12	15239	0.0259	85	312	13	21	Alpelisib	0.00998	treatment	72	2	MCF10A-GM_7	397	0.0254	635.9	71.1	15071	356.7	0.0231	0.00232	1.0049
Alpelisib	180619_MC_12	14657	0.0245	69	292	14	4	Alpelisib	0.00998	treatment	72	2	MCF10A-GM_8	361	0.0240	635.9	71.1	15071	356.7	0.0231	0.00096	0.9878
Alpelisib	180619_MC_12	14816	0.0207	67	241	14	10	Alpelisib	0.00998	treatment	72	2	MCF10A-GM_9	308	0.0204	635.9	71.1	15071	356.7	0.0231	-0.00271	0.9925
Alpelisib	180619_MC_10	12737	0.0213	56	216	13	4	Alpelisib	0.033266667	treatment	72	2	MCF10A-GM_1	272	0.0209	635.9	71.1	15071	356.7	0.0231	-0.00217	0.9277
Alpelisib	180619_MC_10	13561	0.0212	58	231	13	13	Alpelisib	0.033266667	treatment	72	2	MCF10A-GM_2	289	0.0209	635.9	71.1	15071	356.7	0.0231	-0.00221	0.9543
Alpelisib	180619_MC_10	12915	0.0177	47	183	14	3	Alpelisib	0.033266667	treatment	72	2	MCF10A-GM_3	230	0.0175	635.9	71.1	15071	356.7	0.0231	-0.00558	0.9335
Alpelisib	180619_MC_11	13333	0.0233	72	241	3	18	Alpelisib	0.033266667	treatment	72	2	MCF10A-GM_4	313	0.0229	635.9	71.1	15071	356.7	0.0231	-0.00014	0.9471
Alpelisib	180619_MC_11	14436	0.0212	46	261	6	7	Alpelisib	0.033266667	treatment	72	2	MCF10A-GM_5	307	0.0208	635.9	71.1	15071	356.7	0.0231	-0.00225	0.9812
Alpelisib	180619_MC_11	13917	0.0181	56	197	14	3	Alpelisib	0.033266667	treatment	72	2	MCF10A-GM_6	253	0.0179	635.9	71.1	15071	356.7	0.0231	-0.00522	0.9654

|<
<<
Previous
Page 24 of 66
Next
>>
>
576 to 600 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)